|
Gene: CSK |
Gene summary for CSK |
Gene summary. |
Gene information | Species | Human | Gene symbol | CSK | Gene ID | 1445 |
Gene name | C-terminal Src kinase | |
Gene Alias | CSK | |
Cytomap | 15q24.1 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A8K3B6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1445 | CSK | LZE4T | Human | Esophagus | ESCC | 1.54e-06 | 1.70e-01 | 0.0811 |
1445 | CSK | LZE7T | Human | Esophagus | ESCC | 2.59e-21 | 5.44e-01 | 0.0667 |
1445 | CSK | LZE22D1 | Human | Esophagus | HGIN | 2.86e-02 | 8.16e-02 | 0.0595 |
1445 | CSK | LZE22T | Human | Esophagus | ESCC | 1.32e-02 | 2.18e-01 | 0.068 |
1445 | CSK | LZE24T | Human | Esophagus | ESCC | 3.22e-08 | 1.71e-01 | 0.0596 |
1445 | CSK | LZE6T | Human | Esophagus | ESCC | 1.91e-05 | 2.49e-01 | 0.0845 |
1445 | CSK | P1T-E | Human | Esophagus | ESCC | 2.84e-15 | 3.53e-01 | 0.0875 |
1445 | CSK | P2T-E | Human | Esophagus | ESCC | 2.34e-18 | 2.72e-01 | 0.1177 |
1445 | CSK | P4T-E | Human | Esophagus | ESCC | 3.74e-26 | 4.67e-01 | 0.1323 |
1445 | CSK | P5T-E | Human | Esophagus | ESCC | 1.32e-05 | 1.04e-01 | 0.1327 |
1445 | CSK | P8T-E | Human | Esophagus | ESCC | 3.59e-17 | 3.19e-01 | 0.0889 |
1445 | CSK | P9T-E | Human | Esophagus | ESCC | 3.74e-13 | 2.16e-01 | 0.1131 |
1445 | CSK | P10T-E | Human | Esophagus | ESCC | 3.11e-13 | 2.18e-01 | 0.116 |
1445 | CSK | P11T-E | Human | Esophagus | ESCC | 2.51e-07 | 2.32e-01 | 0.1426 |
1445 | CSK | P12T-E | Human | Esophagus | ESCC | 5.92e-10 | 1.84e-01 | 0.1122 |
1445 | CSK | P15T-E | Human | Esophagus | ESCC | 3.84e-20 | 2.94e-01 | 0.1149 |
1445 | CSK | P16T-E | Human | Esophagus | ESCC | 2.55e-13 | 2.19e-01 | 0.1153 |
1445 | CSK | P19T-E | Human | Esophagus | ESCC | 8.42e-11 | 4.29e-01 | 0.1662 |
1445 | CSK | P20T-E | Human | Esophagus | ESCC | 2.80e-12 | 1.77e-01 | 0.1124 |
1445 | CSK | P21T-E | Human | Esophagus | ESCC | 1.17e-16 | 1.26e-01 | 0.1617 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000689215 | Esophagus | ESCC | post-Golgi vesicle-mediated transport | 82/8552 | 104/18723 | 4.00e-12 | 1.55e-10 | 82 |
GO:0031669110 | Esophagus | ESCC | cellular response to nutrient levels | 148/8552 | 215/18723 | 4.58e-12 | 1.76e-10 | 148 |
GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
GO:0051348111 | Esophagus | ESCC | negative regulation of transferase activity | 177/8552 | 268/18723 | 1.08e-11 | 4.00e-10 | 177 |
GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
GO:004339320 | Esophagus | ESCC | regulation of protein binding | 135/8552 | 196/18723 | 3.69e-11 | 1.22e-09 | 135 |
GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
GO:009887615 | Esophagus | ESCC | vesicle-mediated transport to the plasma membrane | 99/8552 | 136/18723 | 1.13e-10 | 3.39e-09 | 99 |
GO:0042326111 | Esophagus | ESCC | negative regulation of phosphorylation | 237/8552 | 385/18723 | 1.86e-10 | 5.33e-09 | 237 |
GO:0009267110 | Esophagus | ESCC | cellular response to starvation | 110/8552 | 156/18723 | 2.63e-10 | 7.37e-09 | 110 |
GO:00434143 | Esophagus | ESCC | macromolecule methylation | 199/8552 | 316/18723 | 3.44e-10 | 9.57e-09 | 199 |
GO:004259419 | Esophagus | ESCC | response to starvation | 133/8552 | 197/18723 | 4.31e-10 | 1.14e-08 | 133 |
GO:0052547111 | Esophagus | ESCC | regulation of peptidase activity | 275/8552 | 461/18723 | 7.54e-10 | 1.88e-08 | 275 |
GO:003367319 | Esophagus | ESCC | negative regulation of kinase activity | 154/8552 | 237/18723 | 1.38e-09 | 3.27e-08 | 154 |
GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
GO:00070419 | Esophagus | ESCC | lysosomal transport | 83/8552 | 114/18723 | 3.52e-09 | 7.41e-08 | 83 |
GO:190547519 | Esophagus | ESCC | regulation of protein localization to membrane | 117/8552 | 175/18723 | 1.14e-08 | 2.26e-07 | 117 |
GO:0051100111 | Esophagus | ESCC | negative regulation of binding | 109/8552 | 162/18723 | 2.10e-08 | 4.03e-07 | 109 |
GO:0070997111 | Esophagus | ESCC | neuron death | 216/8552 | 361/18723 | 3.49e-08 | 6.45e-07 | 216 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0512018 | Esophagus | ESCC | Epithelial cell signaling in Helicobacter pylori infection | 52/4205 | 70/8465 | 2.17e-05 | 1.07e-04 | 5.47e-05 | 52 |
hsa0512019 | Esophagus | ESCC | Epithelial cell signaling in Helicobacter pylori infection | 52/4205 | 70/8465 | 2.17e-05 | 1.07e-04 | 5.47e-05 | 52 |
hsa051202 | Liver | HCC | Epithelial cell signaling in Helicobacter pylori infection | 50/4020 | 70/8465 | 3.96e-05 | 2.16e-04 | 1.20e-04 | 50 |
hsa051203 | Liver | HCC | Epithelial cell signaling in Helicobacter pylori infection | 50/4020 | 70/8465 | 3.96e-05 | 2.16e-04 | 1.20e-04 | 50 |
hsa0512010 | Oral cavity | OSCC | Epithelial cell signaling in Helicobacter pylori infection | 49/3704 | 70/8465 | 7.57e-06 | 3.59e-05 | 1.83e-05 | 49 |
hsa0512017 | Oral cavity | OSCC | Epithelial cell signaling in Helicobacter pylori infection | 49/3704 | 70/8465 | 7.57e-06 | 3.59e-05 | 1.83e-05 | 49 |
hsa0512024 | Oral cavity | LP | Epithelial cell signaling in Helicobacter pylori infection | 38/2418 | 70/8465 | 5.17e-06 | 4.20e-05 | 2.71e-05 | 38 |
hsa0512034 | Oral cavity | LP | Epithelial cell signaling in Helicobacter pylori infection | 38/2418 | 70/8465 | 5.17e-06 | 4.20e-05 | 2.71e-05 | 38 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CSK | SNV | Missense_Mutation | novel | c.115N>C | p.Val39Leu | p.V39L | P41240 | protein_coding | tolerated(0.52) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CSK | SNV | Missense_Mutation | rs780001574 | c.296N>T | p.Pro99Leu | p.P99L | P41240 | protein_coding | tolerated(0.07) | benign(0.26) | TCGA-VS-A9UP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
CSK | SNV | Missense_Mutation | rs749945630 | c.760N>A | p.Val254Met | p.V254M | P41240 | protein_coding | deleterious(0.01) | probably_damaging(0.94) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CSK | SNV | Missense_Mutation | rs200009296 | c.167N>A | p.Arg56His | p.R56H | P41240 | protein_coding | tolerated(0.07) | benign(0.011) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CSK | SNV | Missense_Mutation | c.946G>A | p.Ala316Thr | p.A316T | P41240 | protein_coding | deleterious(0) | possibly_damaging(0.9) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
CSK | SNV | Missense_Mutation | c.956A>G | p.Asn319Ser | p.N319S | P41240 | protein_coding | deleterious(0) | probably_damaging(0.934) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CSK | SNV | Missense_Mutation | rs754136671 | c.682N>A | p.Ala228Thr | p.A228T | P41240 | protein_coding | tolerated(0.56) | possibly_damaging(0.527) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CSK | SNV | Missense_Mutation | c.952C>T | p.Arg318Cys | p.R318C | P41240 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AG-A01W-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
CSK | SNV | Missense_Mutation | novel | c.454N>A | p.Leu152Met | p.L152M | P41240 | protein_coding | tolerated(0.51) | probably_damaging(0.969) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CSK | SNV | Missense_Mutation | novel | c.103N>A | p.Val35Met | p.V35M | P41240 | protein_coding | tolerated(0.19) | benign(0.138) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1445 | CSK | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | 223365983 | RIVOCERANIB | |
1445 | CSK | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | 936563-93-8 | |||
1445 | CSK | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | hydrochlorothiazide | HYDROCHLOROTHIAZIDE | 31327267 | |
1445 | CSK | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | 252827493 | ||
1445 | CSK | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | 249565754 | ||
1445 | CSK | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | BBI503 | |||
1445 | CSK | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
Page: 1 |